Birmingham, AL – 11 July 2011 – Soluble Therapeutics, Inc. a Birmingham, Alabama–based CRO specializing in formulation optimization for protein-based therapeutics announces the closing of a $1MM investment that includes funds from The Birmingham Technology Fund, Greer Capital, and Targeted Technology Fund. This investment represents confidence from a group that has a strong track record of investing in companies with solid growth histories and clear paths to profitability focused on serving the needs of the pre-clinical drug discovery market.
This investment will allow Soluble Therapeutics, Inc. to complete the company expansion and continue its mission to accelerate the HSCTMTechnology into the marketplace.
Soluble Therapeutics’ CEO, Dr. Joseph Garner states that “this investment comes at a perfect time for Soluble Therapeutics; it will allow us to immediately expand our capacity to meet market demand for our formulation services.”
Targeted Technology Fund is the newest investor to back Soluble Therapeutics with the closing of this round , and it is led by Managing Partner, Dr. Paul Castella, a seasoned entrepreneur with a history of investing in biotechnology companies with the potential to meet aggressive profitability goals. “This investment in Soluble Therapeutics represents our confidence in the HSCTM Technology and its ability to capture market share quickly” states Dr. Castella.
About Soluble Therapeutics, Inc.
Soluble Therapeutics, Inc. was founded in 2008 to commercialize the HSC™ Technology. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics. Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics’ management team consists of science industry professionals bringing over 60 years combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Soluble Therapeutics, Inc. is the first to introduce protein formulation solutions that deliver the price and performance advantages of the HSCTM Technology. For additional information visit www.soluble-therapeutics.com